About UsOur SciencePipelinePublicationsNewsContactCareers →
Home/News
Newsroom

News & announcements

Company news, financing milestones, and clinical program updates from cAMPfield Therapeutics.

Oct 9, 2026

Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara’s Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD

Clinical · Prifemilast
Read →
Aug 3, 2026

cAMPfield Strengthens Leadership Team with Key Executive Appointments, Including Graham Heap, MD, PhD as President, R&D

Leadership · Company
Read →
Jun 18, 2026

cAMPfield Launches With $180 Million Series A to Develop Oral PDE4B Inhibitor for IBD

Financing · Company
Read →

Media inquiries

For interviews, assets, or background, reach the cAMPfield communications team.

contact@campfieldtx.com →
© 2026 cAMPfield Therapeutics, Inc.Privacy · Terms · Forward-Looking Statements